Leerink Partnrs Brokers Boost Earnings Estimates for Hookipa Pharma Inc (NASDAQ:HOOK)

Hookipa Pharma Inc (NASDAQ:HOOK) – Analysts at Leerink Partnrs increased their Q2 2024 earnings per share estimates for Hookipa Pharma in a research note issued on Wednesday, July 24th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of ($1.48) per share for the quarter, up from their prior estimate of ($1.50). The consensus estimate for Hookipa Pharma’s current full-year earnings is ($2.57) per share. Leerink Partnrs also issued estimates for Hookipa Pharma’s Q3 2024 earnings at ($1.03) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 earnings at ($1.33) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($1.57) EPS and FY2027 earnings at ($1.01) EPS.

Several other brokerages also recently weighed in on HOOK. HC Wainwright upped their target price on Hookipa Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, June 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Hookipa Pharma in a research report on Tuesday, May 21st. Finally, JMP Securities decreased their target price on Hookipa Pharma from $50.00 to $23.00 and set a “market outperform” rating for the company in a research report on Friday.

Hookipa Pharma Price Performance

Shares of NASDAQ HOOK opened at $6.15 on Friday. Hookipa Pharma has a 1-year low of $4.10 and a 1-year high of $11.30. The business has a 50-day moving average of $7.01 and a 200-day moving average of $7.30. The company has a market capitalization of $60.89 million, a price-to-earnings ratio of -1.23 and a beta of 0.81.

Hookipa Pharma (NASDAQ:HOOK) last posted its quarterly earnings results on Thursday, May 9th. The company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $2.40. Hookipa Pharma had a negative return on equity of 33.33% and a negative net margin of 88.73%. The firm had revenue of $36.60 million during the quarter, compared to the consensus estimate of $3.20 million. During the same quarter in the previous year, the business earned ($2.70) earnings per share.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hookipa Pharma stock. Virtu Financial LLC acquired a new stake in shares of Hookipa Pharma Inc (NASDAQ:HOOK) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 43,021 shares of the company’s stock, valued at approximately $31,000. Institutional investors own 63.88% of the company’s stock.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.